A scientific breakthrough that began in the 1980s has now received one of the highest honors in global science. Researchers Swee Lay Thein and Stuart Orkin were awarded the Breakthrough Prize in Life Sciences for the foundational research that helped make Casgevy possible.
The therapy relies on the gene-editing technology CRISPR to treat Sickle Cell Anemia and beta-thalassemia, serious blood disorders that can cause severe pain and life-threatening complications.
The award ceremony was held in Los Angeles on April 18 and highlighted the technology’s major impact on medicine. The treatment works by switching off a specific gene, enabling the body to once again produce healthy blood cells. For many patients who endure painful crises and organ damage, the therapy offers a dramatic improvement in quality of life.
Early Symptom Observation Led to Breakthrough
The foundation for this medical advancement came from an observation made decades ago. Physician Janet Watson discovered that babies genetically predisposed to sickle cell anemia did not develop symptoms immediately after birth. Instead, signs of the disease appeared several months later.
Scientists later learned that newborns produce fetal hemoglobin, which protects red blood cells.As children grow, their bodies replace fetal hemoglobin with adult hemoglobin, triggering the disease.
While researching families affected by less severe forms of the disease, Swee Lay Thein found that some individuals continued producing fetal hemoglobin throughout their lives. Her work revealed that a gene known as BCL11A functions like a switch that shuts down the production of this protective form of hemoglobin.
Switching Genes to Maintain Healthy Blood Production
Researchers then focused on disabling that switch so the body could keep producing healthy blood cells even during adulthood.
Although Casgevy can function as a cure, it remains complex and expensive. Clinicians extract bone marrow cells, modify them in a lab, and reinfuse them after chemotherapy.
The procedure can be physically demanding, and its price can reach several million dollars, limiting access for patients in lower-resource regions.
Scientists are now working to make the therapy simpler and more accessible. One major goal is to develop techniques that deliver gene editing via injection, eliminating lengthy hospital stays. Researchers hope these advances will make the therapy available to more people who urgently need it.
Read the original article on: metropoles
Read more:A startup says it created human sperm in a lab and used it to form embryos